A Study of BI 3810944 in Patients With Advanced Cancer

This study is open to adults with advanced cancer (solid tumours) for whom previous treatment was not successful, or no treatment exists. The study tests different doses of BI 3810944 to find out which doses they can tolerate. Another purpose is to identify the most suitable dose of BI 3810944 and to find out whether it helps people with advanced cancer. BI 3810944 may help fight cancer. Participants get BI 3810944 usually once every 3 weeks. At treatment start, it is given once a week for a short time. Participants may continue to get BI 3810944 as long as they benefit from treatment but no

Trial Details

NCT ID
NCT07224425
Phase
PHASE1
Sponsor
Boehringer Ingelheim
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • BI 3810944
Locations (sample)
  • Louisville, Kentucky, United States|38.25424,-85.75941
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Houston, Texas, United States|29.76328,-95.36327
  • Charlottesville, Virginia, United States|38.02931,-78.47668
  • Brussels, Belgium|50.85045,4.34878

Key Eligibility Criteria

  • Trial participant population specifically to Part A and B:
  • Part A only: participants with any histologically or cytologically confirmed diagnosis of solid tumour who failed conventional treatment or for who…
  • Part B only: participants with histologically or cytologically confirmed diagnosis of who has progressed on, or is intolerant to available standard…
  • Eastern cooperative oncology group (ECOG) performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →